Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cangrelor→

Cangrelor Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
163706-06-7
Molecular formula
C17H25Cl2F3N5O12P3S2
Molecular weight
776.4 g/mol
Drug class
Direct, reversible intravenous P2Y12 platelet ADP-receptor antagonistantiplatelet agent
Mechanism of action
Directly and reversibly blocks platelet P2Y12 receptors, preventing ADP-mediated activation of the glycoprotein IIb/IIIa complex and platelet aggregation. Its rapid onset and short offset are related to its intravenous administration and rapid plasma clearance.
Indications / reported uses
  • Adjunct to percutaneous coronary intervention (PCI) to reduce periprocedural myocardial infarction, repeat coronary revascularisation and stent thrombosis in patients not treated with an oral P2Y12 inhibitor and not receiving a glycoprotein IIb/IIIa inhibitor

Sources: US DailyMed — KENGREAL (cangrelor), updated October 21 2025 · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cangrelor Environmental Risk Assessment (ERA) (the Cangrelor ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.